How does Melanotan I's half-life affect dosing?

Melanotan I has a plasma half-life of ~2-30 days (implant); ~30 min SubQ, which is short enough to require multiple daily doses to maintain therapeutic exposure. The receptor occupancy curve under 1x daily during loading; less frequent maintenance dosing at 0.5-1 mg per dose explains the typical onset timeline for metabolic and glycemic endpoints.

What route should I use for Melanotan I?

Melanotan I is delivered by subq/implant (approved formulation). Subcutaneous administration is standard for ${o.cat.toLowerCase()} class peptides and provides reliable systemic bioavailability. The choice depends on target system and convenience.

Is Melanotan I safe during pregnancy or breastfeeding?

Melanotan I, like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

What is the standard dosing protocol for Melanotan I?

Conventional Melanotan I dosing is 0.5-1 mg 1x daily during loading; less frequent maintenance via subq/implant (approved formulation). For metabolic and glycemic use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

Home/ Compounds/ Melanotan I

Melanotan I

Metabolic

Metabolic-medicine specialists evaluate Melanotan I against glycemic control, insulin sensitivity, visceral adiposity, and the broader cardiometabolic risk profile. Selective melanocortin-1 receptor (MC1R) agonist Increases eumelanin production in melanocytes. Provides photoprotection. Lacks the MC4R-mediated central effects (libido, appetite, sexual response) of Melanotan II.. Baseline labs (HbA1c, fasting glucose, fasting insulin, HOMA-IR, lipid panel, ALT/AST, hsCRP) with 6-8 week follow-up on the 0.5-1 mg 1x daily during loading; less frequent maintenance protocol provide the clinical evaluation framework.

Metabolic / Endocrine Applications

Glucose RegulationAppetite RegulationType 2 Diabetes ResearchFatty Liver ResearchAMPK Activation

Key Takeaways

Metabolic lens: Melanotan I is tracked against glycemic, insulin sensitivity, visceral adiposity, and inflammatory markers.
Mechanism: Selective melanocortin-1 receptor (MC1R) agonist.
Metabolic monitoring: baseline HbA1c, fasting glucose, fasting insulin, HOMA-IR, hsCRP, ALT/AST; ideally CGM in first cycle.
Metabolic dose: 0.5-1 mg 1x daily during loading; less frequent maintenance via subq/implant (approved formulation).
Metabolic-medicine stack partners: Semaglutide (GLP-1), Cagrilintide, MOTS-c.

Metabolic / Endocrine Mechanism

Selective melanocortin-1 receptor (MC1R) agonist. Increases eumelanin production in melanocytes. Provides photoprotection. Lacks the MC4R-mediated central effects (libido, appetite, sexual response) of Melanotan II. The metabolic medicine framework evaluates Melanotan I against four pathway-level endpoints: insulin signalling and glycemic control, AMPK and mitochondrial function, visceral fat and cardiometabolic risk, and the appetite-satiety axis. The subsections below cover each.

AMPK and mitochondrial signalling

Independent of insulin-receptor pharmacology, several peptides in this category engage AMPK and mitochondrial biogenesis pathways. Melanotan I engages this layer indirectly through its effect on adiposity, inflammation, and the broader metabolic milieu. The practical effect is sustained shifts in fasting insulin, fasting glucose, and energy expenditure that are not visible in single-meal glycemic curves but accumulate across a cycle.

Insulin signalling and glycemic effect

Melanotan I's relationship to insulin signalling is one of the central practical considerations. Direct incretin-axis effects are limited, but downstream insulin sensitivity is influenced through inflammatory, mitochondrial, or weight-related mechanisms. The implication for glycemic monitoring is clear: baseline HbA1c, fasting glucose, and — ideally — a CGM during the first cycle for users in or near the diabetes-spectrum range.

Weight management and the appetite circuit

Appetite suppression and slowed gastric emptying are direct effects of Melanotan I, with implications for muscle mass preservation, dietary composition, and the rate of intentional weight loss. Pairing with adequate protein intake and resistance training is the standard approach for users targeting weight reduction.

Metabolic / Endocrine Applications

Gastric Emptying

Melanotan I for gastric emptying is best-evaluated against baseline metabolic markers: fasting glucose, HbA1c, lipid panel, hsCRP, ALT/AST. Response timelines are typically 8–12 weeks for primary endpoints; secondary markers (inflammation, hepatic function) move on similar timescales.

Fatty Liver Research

Where Melanotan I is used for fatty liver research, integration with GLP-1 agonist therapy, AMPK activators, or visceral-fat-selective agents is the standard pattern in metabolic medicine clinics. Mono-therapy is appropriate for first-cycle users and for milder presentations.

Type 2 Diabetes Research

In the metabolic syndrome population, Melanotan I for type 2 diabetes research produces measurable shifts on the cardiometabolic axis when paired with appropriate dietary and activity inputs. The compound's effect is additive to lifestyle rather than substitutive for it.

AMPK Activation

Melanotan I for ampk activation is best-evaluated against baseline metabolic markers: fasting glucose, HbA1c, lipid panel, hsCRP, ALT/AST. Response timelines are typically 8–12 weeks for primary endpoints; secondary markers (inflammation, hepatic function) move on similar timescales.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	0.5-1 mg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	1.5-1 mg	4–6 weeks initial cycle
Metabolic focus	SubQ	0.5-1 mg	1x daily during loading; less frequent maintenance
Maintenance phase	SubQ	1.5-1 mg	Ongoing with periodic pauses

Dose timing for Melanotan I is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

Melanotan I stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from metabolic medicine specialists.

Melanotan I + Semaglutide (GLP-1): Selective GLP-1 receptor agonist. Pairs naturally with Melanotan I's mechanism in metabolic / endocrine protocols.
Melanotan I + Cagrilintide: Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex). Pairs naturally with Melanotan I's mechanism in metabolic / endocrine protocols.
Melanotan I + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with Melanotan I's mechanism in metabolic / endocrine protocols.
Melanotan I + Tesamorelin: Modified GHRH (1-44) sequence with an N-terminal trans-3-hexenoic acid that confers resistance to DPP-4 cleavage. Pairs naturally with Melanotan I's mechanism in metabolic / endocrine protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Approved (Scenesse implant for EPP) Research: Phase III in EPP; off-label tanning use

Hyperpigmentation (intended). Nausea on initial doses. Watch for new/changing moles. Avoid in personal/family melanoma history.

Lens-specific safety considerations for metabolic / endocrine use of Melanotan I: Hyperpigmentation (intended). Nausea on initial doses. Watch for new/changing moles. Avoid in personal/family melanoma history. Additional metabolic / endocrine monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Afamelanotide in erythropoietic protoporphyria

PMID 26177253

Melanotan I vs Related Peptides

Compound	Profile	Onset	Best For
Melanotan I	α-MSH analogue (long-acting)	~2-30 days (implant); ~30 min SubQ	Metabolic
Semaglutide (GLP-1)	GLP-1 receptor agonist	~7 days	The blockbuster GLP-1 receptor agonist with weekly dosing — engineered from native GLP-1 for protease resistance and albumin binding
Cagrilintide	Long-acting amylin analogue	~7 days	A long-acting amylin analogue paired with semaglutide for weight loss results that exceed either drug alone
Tesamorelin	Stabilised GHRH analogue	~30 min	An FDA-approved long-chain GHRH analogue used for HIV-associated lipodystrophy and notable for its consistent effect on visceral adipose reduction

Frequently Asked Questions

How does Melanotan I affect glycemic control?

Melanotan I's effect on glycemic markers depends on its primary mechanism. Direct incretin and amylin agonists produce rapid and substantial shifts in fasting glucose and post-prandial response; compounds engaging insulin sensitivity indirectly produce more gradual shifts. Baseline HbA1c and — ideally — a CGM in the first cycle clarifies the individual response.

Will Melanotan I affect my muscle mass during weight loss?

Aggressive weight loss without adequate protein intake and resistance training results in significant lean-mass loss with most metabolic compounds, including Melanotan I. Pairing the metabolic protocol with 1.6–2.0 g/kg/day protein and twice-weekly resistance training preserves lean mass during the cut. This is now standard of care in metabolic medicine clinics.

What weight loss can I expect?

Melanotan I-attributable weight loss varies substantially by compound class, baseline body composition, and dietary and activity context. Direct incretin agonists produce the largest effect sizes in current literature; other peptide classes contribute more modestly and primarily through metabolic flexibility and inflammation reduction. Total trajectory matters more than first-month results.

Will I regain weight after stopping Melanotan I?

For most compounds in this class, partial weight regain after discontinuation is the typical pattern unless dietary and activity inputs have been fundamentally changed during the cycle. Metabolic-medicine practice increasingly frames peptide therapy as chronic rather than time-limited for weight management indications.

What is Melanotan I?

Melanotan I (also known as Afamelanotide / Scenesse) is a 13-residue α-msh analogue (long-acting) with a molecular weight of 1646 Da and a plasma half-life of ~2-30 days (implant); ~30 min SubQ. Selective melanocortin-1 receptor (MC1R) agonist. Increases eumelanin production in melanocytes. Provides photoprotection. Lacks the MC4R-mediated central effects (libido, appetite, sexual response) of Melanotan II. The compound is studied primarily in the metabolic / endocrine domain for the applications outlined above.

How does Melanotan I affect glycemic and metabolic markers?

Melanotan I's metabolic effects depend on whether it engages the incretin-amylin axis directly or operates through inflammation, mitochondrial, or adiposity pathways. Effects on glycemic markers tend to be gradual and operate through metabolic flexibility, inflammation reduction, and adiposity changes. Baseline HbA1c, fasting insulin, and — ideally — CGM during the first cycle clarify individual response.

Clinical Protocol

Start a Melanotan I Protocol

Alukard provides physician-supervised metabolic protocols with GMP-certified Melanotan I and GMP-certified compounds with comprehensive metabolic and glycemic monitoring.

Get Protocol

Quick Facts

Molecular weight: 1646 Da
Sequence length: 13 aa
Half-life: ~2-30 days (implant); ~30 min SubQ
WADA: Not on prohibited list
FDA: Approved (Scenesse implant for EPP)
Research: Phase III in EPP; off-label tanning use

Stack Partners

Semaglutide (GLP-1)

Cagrilintide

MOTS-c

Tesamorelin

AOD-9604

Research Note

All metabolic / endocrine applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Melanotan I unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised metabolic protocols

Start Your Metabolic / Endocrine Protocol for Melanotan I

Alukard provides physician-supervised metabolic protocols with GMP-certified compounds with comprehensive metabolic and glycemic monitoring.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised